DUBLIN, IRELANDÂ —(Marketwired – February 10, 2016) –
Research and Markets
has announced the addition of the “Antibody Drug Conjugates Market (3rd Edition)” report to their offering.
The Antibody Drug Conjugates Market (3rd edition), 2015–2025 report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market has been one of the most actively evolving markets over the last few years and encompasses a myriad of therapies that can be potentially exploited for a broad range of cancer indications.Â
The ADC market is being driven by the sales of ADCETRIS® and KADCYLA®, the only two commercially available drugs. It is a relatively new concept with respect to technology, although the individual molecules that form ADCs have been used long since. This new class of therapeutics has witnessed a strong acceptance from both big and small pharmaceutical companies as they try to fill gaps in their respective oncology pipelines.
One of the key objectives of the study is to review and quantify the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With two marketed drugs (ADCETRIS® and KADCYLA®), the market is treading its way towards fulfilling a huge untapped promise.Â
Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry's evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.
Amongst other elements, the report elaborates on the following key areas:
– The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre–clinical) and indications targeted
– Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs
– Recent partnerships that have taken place over the last decade including product co–development, licensing and clinical trial collaborations
– Various investments and grants received by the companies focused in this area
– Therapeutic areas forming the current focus of developers, the gradual drift and expansion towards broader application areas
– Competitive landscape and inherent threats to growth in the short and long term
– Development and sales potential, based on target consumer segments, likely adoption rate and expected pricing, of molecules in late stages of development
The base year for the report is 2015. The report provides market forecast for the period 2015–2025. The research, analysis and insights presented in this report include potential sales of several ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.
Example Highlights
– Driven by the sales of ADCETRIS® and KADCYLA® (the only two drugs currently available commercially), the ADC market is estimated to be worth around USD 0.9 billion in 2015.
– The market has a strong clinical pipeline of 53 molecules; nearly one–third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/discovery stage; in our research, we came across over 60 such molecules.
– Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
– Roche, with six molecules in clinical development, has the most developed pipeline of ADCs. Other established players in the market are (in alphabetical order) AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, GSK, Novartis, Pfizer and Sanofi.
– Relative new entrants include (in alphabetical order) AbGenomics, Allozyne, Ambrx, Biotest, Celldex Therapeutics, Centrose, CytomX Therapeutics, Esperance Pharmaceuticals, Formation Biologics, Genmab, Heidelberg Pharma, Igenica, Immunomedics, Oxford BioTherapeutics, Kairos Therapeutics, Merrimack Pharmaceuticals, Mersana Therapeutics, NBE Therapeutics, Philochem, PhotoBiotics, Progenics Pharmaceuticals, Sorrento Therapeutics, Stem CentRx, Sutro Biopharma, Synthon, Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
– About 70%–80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
– Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety/efficacy profile.
– With around 10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2025.Favourable market environment and regulatory regimes could result in an even steeper growth.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. KOL Analysis
6. Key Therapeutic Areas For ADCS
7. Upcoming ADC Drugs: Detailed Profiles And Market Forecast
8. Partnerships And Collaborations
9. Venture Capital Interest
10. Company Profiles
AAIPharma Services Corp
AB SCIEX
ACES Pharma
ADC Therapeutics
AIDS Malignancy Consortium
ALMAC Group
AMRI Global
ARCH Venture Partners
AbGenomics
AbbVie
Abramson Cancer Center of the University of Pennsylvania
Abraxis BioScience
Academic Medical Center, University of Amsterdam
Academic and Community Cancer Research United
Adimab
Advanced Biotechnologies Venture Fund
Advantage Capital Partners
Advent Venture Partners
Affinity Lifesciences
Agensys
Alexandria Real Estate Equities
Algeta
Allos Therapeutics
Allozyne
Alta Partners
Ambrx
American Cancer Society
American Society of Clinical Oncology (ASCO)
American Society of Haematology, San Francisco
AmerisourceBergen Corporation
Amgen
Amgen Ventures
Apax Partner
Apposite Capital
Aravis Ventures
Asan Medical Center
Aspyrian Therapeutics
Astellas Pharma
AstraZeneca
Asymchem
Auven Therapeutics
Avid Biologics
BSI
BSP Pharmaceuticals
Bachem
BankInvest Group
Barbara Ann Karmanos Cancer Institute
Baxter BioPharma Solutions
Bayer Healthcare
Bear Sterns Health Innoventures
Beatson West of Scotland Cancer Center
BioAgilytix Labs
BioOutsource
BioPharma Solutions
BioWa
Biogen Idec
Biotechnique
Biotecnol
Biotest
Boehringer Ingelheim
Boehringer Ingelheim Venture Fund
Bristol–Myers Squibb
Brown University
CARBOGEN AMCIS
CMC Biologics
CTI Life Sciences Fund
Cambrex Corporation
Canaan Partners
Cancer Institute of Lorraine
Cancer Research Technology (CRT), UK
Cancer Research, UK
Cancer Treatment Centers of America
Cantonal Hospital of St. Gallen
Cardinal Health
Carnegie Kapitalforvaltning
Cascade Investment
Casdin Capital
Catalent Pharma Solution
Catapult Ventures
Celgene
Celldex Therapeutics
Centers for Disease Control and Prevention
Centre Hospitalier Lyon Sud, France
Centre Oscar Lambret
Centrose
ChemCon
ChemPartner
Children's Oncology Group
Chu de Limoges
Chugai Pharmaceutical
City of Hope Medical Center
Coldstream Laboratories
Columbia University
Concortis
Cooley Godward Kronish
Cormorant Asset Management
Creative Biolabs
Credit Suisse First Boston Next Fund
Crocker Ventures
CuraGen
Cytogen Corporation
CytomX Therapeutics
Cytovance Biologics LLC
Daiichi Sankyo
Dalton Pharma Services
Dana–Farber Cancer Institute
Dansk Erhvervsinvestering
Deerfield Management
Dendreon Corporation
Dishman Group
Dow Venture Capital
Duquesne Capital Management
ECOG–ACRIN Cancer Research Group
EirGenix
Eisai
Elder Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Endocyte
Esperance Pharmaceuticals
Eucodis
European Organisation for Research and Treatment of Cancer
Evonik
Expansion Venture Capital
FUJIFILM Diosynth Biotechnologies
Ferring Pharmaceuticals
Ferro Pfanstiehl
Fidelity Biosciences
Fidelity Investments
Formation Biologics
Formosa Laboratories
Fox Chase Cancer Center
Fred Alger Management
GLOBOCAN
GSK
GTC Biotherapeutics
Genentech
General Hospital Linz
Genmab
Genzyme
German Federal Ministry of Education and Research
Gilead Sciences
Glynn Capital Management
Goodwin Biotechnology
Guys Hospital
H&Q Life Sciences Investments
H. Lee Moffitt Cancer Center & Research Institute Dept of Onc
HBM BioVentures
HBM Partners
HNI Holdings
Hambrecht & Quist Capital Management
Harris and Harris Group
Hartmann Oncology Radiotherapy Group
HealthCap Venture Capital
Heidelberg Pharma
Heraeus
Hercules Technology Growth Capital
Hospital Ramon y Cajal, Madrid, Spain
Hospital Saint–Louis
Hospital Universitario de Salamanca
ICM
IDT Australia
INC Research
IRCCS AOU San Martino
IUHealth Goshen Center for Cancer Care
Igenica
ImClone Systems
Immunogen
Immunomedics
Index Ventures
Innovis Investments
Innsbruck Medical University
Institut Bergonié, Bordeaux
Institut Curie
International Biotechnology Trust
Invenra
Iroquois Capital Group
JAFCO
Janssen Biotech
Jennison Associates
Johnson & Johnson
Jules Bordet Institute
Kairos Therapeutics
Karolinska university hospital
Kemwell
Korea Cancer Center Hospital
LODH Private Equity Partners
Leica Biosystems
Leukaemia and Lymphoma Society
Life Science Pharmaceuticals
Ligand Pharmaceuticals
Lilly Ventures
Lombard Odier Darier Hentsch & Cie
Lonza
Lymphoma Study Association
M D Anderson Cancer Center
MAB Discovery
MPM Capital
MS Seed Capital
MS Ventures
MacroGenics
Massachusetts General Hospital
Maverick Capital
Mayo Clinic
McKesson Corporation
MedImmune
MedStar Washington Hospital Center
Medarex
Medical College of Wisconsin
Medical University of Vienna
Medivation
Memorial Sloan–Kettering Cancer Center
Menarini
Merck
Merrimack Pharmaceuticals
Mersana Therapeutics
MiMabs
Millenium Pharmaceuticals
Modal Capital L.P.
Molecular Insight Pharmaceuticals
Morphotek
NBE Therapeutics
NSABP Foundation
Natco Pharma
National Cancer Center of Korea
National Cancer Institute
National Research Council of Canada
New Enterprise Associates
New York Medical College
Nextech Venture
Noonday Asset Management
Nordic Nanovector
Norfolk and Norwich Hospital
Northwestern University
Nottingham University Hospitals NHS Trust
Novartis
Novasep
Novella Clinical
OVP Venture Partners
Ohio State University
Oncology Institute of Southern Switzerland
Oncology–Rinat Research and Development (ORRD)
Ono Pharmaceutical
Onyx Pharmaceuticals
Orbimed Advisors
Oslo University Hospital
Oxford BioTherapeutics
Oxford Capital Partners
Pacific GMP
Patheon
Perceptive Advisors
Pfizer
Pfizer Venture Investments
Pharmacyclics
Philochem
Philogen
PhotoBiotics
Pierre Fabre Group
Piramal Pharma Solutions
PolyTherics
Presidio Partners
Princess Margaret Hospital
ProQuest Investments
Progenics Pharmaceuticals
Project Pharmaceutics
PureTech Ventures
QPS Holdings
Quanta BioDesign
Queen Elizabeth Hospital
Recepta Biopharma
Redmile Group
Redwood Bioscience
Regional Center for the Fight Against Cancer
ReqMed Company
Research Corporation Technologies
Roche
Roche Venture Fund
Royal Liverpool Hospital
S. Orsola Malpighi
SAFC
SCRI Innovations
SV Life Sciences
SafeBridge Consultants
Sandoz
Sanofi
Sarah Cannon Research Institute
Scale Venture Partners
Scottish Widows Investment Partnership
Seattle Genetics
Seoul National University Hospital
Seragon Pharmaceuticals
Severance Hospital
Shanghai Fosun Pharma
Sigma–Aldrich Corporation
Silicon Valley Bank
Skyline Ventures
Societa Italiana Corticosteroidi
Society for Neuro–Oncology (SNO), Miami
Sofinnova Ventures
Sorenson Development
Sorrento Therapeutics
South East Growth Fund & Management
Southampton General Hospital
Southwest Oncology Group
Spectrum Pharmaceuticals
Spirogen
St James University Hospital
St. Jude Children's Research Hospital
Stem CentRx
Suez Ventures
Sutro Biopharma
Symbiosis Pharmaceutical Services
Syntarga
Synthon
TPG–Axon Capital
TUBE Pharma
Takeda Pharmaceutical
Tavistock Life Sciences
Tekla Healthcare investors & Tekla Life Science Investors
The Chemistry Research Solution
The Christie Hospital
The Churchill Hospital,UK
The Column Group
The Freeman Hospital
The Institute of Haematology in Bologna
The Methodist Hospital System
Themelios Ventures
Third Rock Ventures
Tuas Biomedical Park
Twilight Venture Partners
UCB Pharma
UCL School of Pharmacy
UCLA Jonsson Comprehensive Cancer Center
UT Southwestern Medical Center
UZ Leuven Hospital
Unilever Technology Ventures Fund B.V.
Union Carbide Employees Pension Plan
Union Chimique Belge
University Hospital of Wales
University Hospital, UK
University Hospitals Seidman Cancer Center
University of Alabama
University of Amsterdam
University of California
University of Cologne
University of Kansas Medical Center Research Institute
University of Modena and Reggio Emilia
University of Munich
University of Oklahoma Stephenson Cancer Center
University of Texas Health Science Center
University of Ulm
University of Washington Cancer Consortium
VLG Investments
Valeant Pharmaceutical
Vanderbilt–Ingram Cancer Center
Venrock Healthcare Capital Partners
Ventana Medical Systems
Venture Associates
Ventures West Capital
Versant Ventures
Victor Hugo Surgical Clinic
Virginia Cancer Specialists, PC
VivaMab
Vulcan Capital
WILEX
WT Investment Advisors Fund
Washington University School of Medicine
Waters
Watson Pharmaceuticals
Weill Medical College of Cornell University
Wellington Management Company
Western Regional Medical Center
Wharton Biotechnology Partners
WuXi PharmaTech
Wyeth
Zhejiang Medicine Co. (ZMC)
Ziff Asset Management
Zroche Venture Fund
Zymework
iBIOSOURCE
For more information visit http://www.researchandmarkets.com/research/c2ctf5/antibody_drug
Sector: Pharmaceuticals